Mounjaro weight loss jab available at GPs

To help people lose weight, prescriptions for Mounjaro Jabs will be present in GP surgeries in the UK since today – but only for those who meet very strict criteria.

Although NHS UK is a need for a gradual approach to reach the most needed, GPs workload and NHS resources, although the long -term plan is more common.

Some GP applications already warn patients who do not meet the criteria that they should not make an appointment to discuss Jabs right now.

Pharmacy trade organizations say that the demand for Mounjaro from GPS will exceed the supply.

Mounjaro or Tirzepathide is a weekly licensed injection to help Type 2 diabetes treatment, but now prescribed to help those who are obesity to lose weight.

The drug makes you feel fuller, so you eat less food. In clinical studies, people who took it lost 20% of body weight.

According to NHS UK, the first group of patients who can get JAB from GPs or a community clinic will be the most needed.

These people:

• A BMI 40 or more (or minority ethnicity 37.5)
• And the following conditions were five of the following: Type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol and obstructive sleep apnea

People will also receive “winded” care – for example, including the exercise of a healthy diet and support for monitoring.

However, prescriptions for the drug will not necessarily be available from all local GPs. In some cases, it will come from other primary care services.

NHS, UK says that people should check the Integrated Maintenance Board (ICB) website for more information. (This is the organization responsible for planning health services for a local population).

Dr. Claire Fuller, Primary Layer Maintenance Director in the UK, says that more access to weight loss drugs will make a “significant difference in people’s lives” living with obesity and living with serious patient health.

“This is an important step in the introduction of weight loss drugs, community -based services can offer this treatment today.” He said.

However Some GP applications They published notifications on websites. Very few patients on their lists It is entitled to the drug immediately and if someone does not meet the criteria, it should not make an appointment.

He says that other weight loss services such as workshops and applications are available in messages.

A GP surgery asked patience Community services are established.

According to the Great Pharmacists Trade Association, the Company Chemists Association, all patients who want Mounjaro and meet the criteria are not likely to take it immediately.

Malcolm Harrison, Chairman of the Executive Board, said that although the drugs are likely to “transform their lives” of millions of people, “the planned GP provision is not likely to meet the patient demand,” he said.

And weight loss jabs are relatively new in terms of health. Some GPs and other health personnel need training on how to offer them safely and appropriately.

Mounjaro also requires monthly controls for patients in the first few months of receiving, which makes it an intensive process for doctors.

Surgery will also look at the capacity to provide the necessary winding care as well as injection.

Then there will be those who can’t get Mounjaro right now – for example, women who try to be pregnant, pregnant or breastfeed.

People with certain conditions, such as pancreatitis or some thyroid tumors, should not take the drug.

Individuals will need to chat with GP or clinics to weigh potential side effects.

Mounjaro has been present in NHS weight loss clinics since March.

Wegovy, also known as Semagluid, is another weight loss that works similarly Jab. Specialist NHS weight loss management can be prescribed to certain groups of people under the care of clinics.

Both drugs can be purchased specially.

NHS Dr Claire Fuller from England says that everyone will not be suitable for weight loss medications.

“It is important that everyone who is worried about the impact of their weight on their health discusses the range of NHS support with health professionals.”

NHS Temporary Guidance from England He argues that Mounjaro will be offered to approximately 220,000 people in the next three years.

Existing plans show that it may be available in stages:

• June 2026: Expanded to include 35 to 39.9 BMI with four of the five conditions listed above
• APRIL 2027: It was also offered to BMI people, only three of the five conditions listed above

Health observer, Nice, will later decide how the presentation is going and decide whether it is time to present it to more people with obesity.

The estimates suggest that approximately 3.4 million people may be appropriate in the next 12 years.

Mounjaro is offered through expert weight management services in NHS in Wales. The Wales government is considering other regulations, including primary maintenance care in the future.

In Northern Ireland, a new regional obesity management service will be provided with a community -based service where patients can access lifestyle support and obesity drugs if they are appropriate.

Currently, very few people are prescribed for weight loss in NHS in Scotland, BBC Scotland News. In Scotland, health committees make decisions about which drugs are present in their regions.